"Death is my Heir"--Ferroptosis Connects Cancer Pharmacogenomics and Ischemia-Reperfusion Injury

Wulf Tonnus; Andreas Linkermann

doi:10.1016/j.chembiol.2016.02.005

"Death is my Heir"--Ferroptosis Connects Cancer Pharmacogenomics and Ischemia-Reperfusion Injury

Cell Chem Biol. 2016 Feb 18;23(2):202-203. doi: 10.1016/j.chembiol.2016.02.005.

Authors

Wulf Tonnus¹, Andreas Linkermann²

Affiliations

¹ Clinic for Nephrology and Hypertension, Christian-Albrechts-University, Kiel 24105, Germany.
² Clinic for Nephrology and Hypertension, Christian-Albrechts-University, Kiel 24105, Germany. Electronic address: andreas.linkermann@uksh.de.

PMID: 26971867
DOI: 10.1016/j.chembiol.2016.02.005

Abstract

Although they are key to precision medicine, pharmacokinetics and pharmacogenomics are currently plagued with inconsistent results. In this issue of Cell Chemical Biology, Shimada et al. (2016) use cell line selectivity and appropriate filters to improve the consistency and to identify biomarkers for the selectivity of lethal compounds. These insights may be useful for our understanding of how necrosis and ischemic injury are regulated.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Apoptosis
Cell Death
Humans
Ischemia
Ischemic Preconditioning
Ischemic Preconditioning, Myocardial
Myocardial Ischemia
Myocardial Reperfusion Injury
Necrosis
Neoplasms
Pharmacogenetics*
Rats, Sprague-Dawley
Rats, Wistar
Reperfusion Injury*
Time Factors
Tumor Necrosis Factor-alpha

Substances

Tumor Necrosis Factor-alpha